Sign In
Buy TCON
$0.0322
+0 (+0%)
At Close: Oct 15, 2025
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2021 Results - Earnings Call Transcript
11:21pm, Wednesday, 11'th Aug 2021
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2021 Results - Earnings Call Transcript
TRACON Pharmaceuticals ends 2Q with $25.6M; remains on track to reveal interim ENVASARC trial data in 2021
04:49pm, Wednesday, 11'th Aug 2021
TRACON Pharmaceuticals reported that it ended its second-quarter 2021 with cash and equivalents of $25.6 million as of June 30, 2021, which doesn't include proceeds from its $15 million underwritten p
TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04:02pm, Wednesday, 11'th Aug 2021
SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
- Trial to Continue as Planned - Trial to Continue as Planned
TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
08:05am, Tuesday, 03'rd Aug 2021
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021
08:05am, Wednesday, 28'th Jul 2021
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TCON Stock Fell 24.54%: Why It Happened
05:43pm, Thursday, 22'nd Jul 2021
The stock price of TRACON Pharmaceuticals Inc (NASDAQ: TCON) fell by 24.54%. This is why it happened.
TRACON Pharmaceuticals upsizes bought deal offering of stock to $15M due to strong demand
09:54am, Thursday, 22'nd Jul 2021
TRACON Pharmaceuticals Inc said it has upsized its previously announced bought deal offering of common stock to $15 million from $10 million due to increased demand to advance the continued clinical d
TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million
10:30pm, Wednesday, 21'st Jul 2021
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commer
TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
05:27pm, Wednesday, 21'st Jul 2021
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commer
TRACON Pharmaceuticals appoints new senior vice president of regulatory affairs and grants inducement equity award
11:24am, Tuesday, 20'th Jul 2021
TRACON Pharmaceuticals (NASDAQ:TCON) said it has appointed Dr Brenda Marczi as its senior vice president, Regulatory Affairs. In her new role Dr Marczi brings more than three decades of regulatory aff
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals announces appointment of Ya Huang as executive director of Statistical Programming
08:20am, Wednesday, 30'th Jun 2021
TRACON Pharmaceuticals Inc. (NASDAQ:TCON) has announced the appointment of Ya Huang as executive director of Statistical Programming. The company noted that Huang brings more than two decades of broad
TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award
08:05am, Wednesday, 30'th Jun 2021
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals announces orphan drug designation for envafolimab in soft tissue sarcoma
11:19am, Tuesday, 29'th Jun 2021
TRACON Pharmaceuticals Inc (NASDAQ:TCON) has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to envafolimab, a novel, single-domain antibody against PD-L1.
